Abstract 1115
Background
Approximately 15% of the 67,000 women diagnosed with metastatic breast cancer (mBC) annually in the U.S. have mTNBC. Few effective treatment options for mTNBC patients have been identified in the past decade & outcomes are poor vs. other mBC subtypes. The objectives of this study were to quantify overall survival (OS) gains in mTNBC from 2010-2015 & project the potential magnitude of OS gains from new therapies approved by 2020.
Methods
We created a simulation model to estimate OS in mTNBC cohorts diagnosed from 2010-2020. OS data were derived from mTNBC clinical trials & were extrapolated to a lifetime horizon by fitting parametric curves. The distribution of 1L regimens used in each diagnosis year came from the IPSOS Global Oncology Monitor - a commercial registry. We projected 2020 OS assuming that 50% of patients receive newly approved therapies (e.g. immunotherapy) & those therapies have an average OS hazard ratio (HR) of 0.7 vs. docetaxel. Scenarios explored alternative HRs of 0.6 & 0.8. We estimated 5-year OS, mean OS & population life year (LY) gains assuming static mTNBC incidence (10,050 cases/year).
Results
From 2010-2015, 5-year OS increased by 2.2% & mean OS increased 1.6 months. If new treatments meet projections for efficacy & market adoption, 5-year mTNBC OS could triple from 5.2% in 2010 to 15.6% in 2020. Over a lifetime horizon, mean per-patient OS could improve by 10.2 months (8,543 population LYs). The population survival gains from 2015-2020 (7,203 LYs) would be ∼5-fold greater vs. gains from 2010-2015 (1,340 LYs). Scenarios with average new treatment HRs of 0.6 & 0.8 resulted in population survival gains of 10,902 LYs & 6,763 LYs vs. 2010.Table: 347P
| Diagnosis Year | 5-Year OS (%) | Mean OS (Months) | Population LYs |
|---|---|---|---|
| 2010 | 5.2 | 22.9 | 19,179 |
| 2015 | 7.4 | 24.5 | 20,519 |
| 2020 (Projected) | 15.6 | 33.1 | 27,721 |
Conclusions
We report modest mTNBC survival gains from 2010 to 2015, but show that clinically meaningful gains could be achieved if new treatments in development achieve realistic levels of effectiveness & are widely adopted. There is high unmet need in mTNBC & these new treatments offer hope for improved future outcomes.
Clinical trial identification
Legal entity responsible for the study
Genentech, Inc.
Funding
Genentech, Inc.
Editorial Acknowledgement
Disclosure
P. Bajaj A. Stein: Employee and stockholder: Genentech, Inc. / F. Hoffmann-La Roche AG. J.A. Roth: Consultant: Genentech; Research funding: Genentech. S.D. Sullivan: Research funding: Genentech, Inc. R. Mahtani: Advisor/consultant: Genentech and has received research support. S.D. Ramsey: Research funding from Genentech, Inc.
Resources from the same session
4742 - Ki67 as an important predictor for Oncotype Dx Recurrence score risk groups in Early Breast cancer
Presenter: Fernando Namuche
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
4697 - Genetic signatures always suggest undertreatment? Experience with PAM51
Presenter: Carolina Sales
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
3158 - Significance of receptors expression, mitotic index and Ki67 in breast cancer patients with Nottingham Prognostic Index (NPI) poor prognosis score
Presenter: Mejri Nesrine
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
3838 - Subgroup analyses of efficacy from a phase III study comparing SB3 (trastuzumab biosimilar) with reference trastuzumab in early breast cancer patients
Presenter: Javier Cortes Castan
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
715 - Autoimmunity and benefit from trastuzumab treatment in breast cancer: results from the HERA phase 3 trial
Presenter: Amir Sonnenblick
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
2388 - Impact of hormone receptor status in HER2+ early breast cancer: a paradigm shift in the trastuzumab era
Presenter: Alexandre De Nonneville
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
3742 - Sefety profile of subcutaneous trastuzumab in patients with HER2-positive early breast cancer: The french HERMIONE non-interventional prospective study
Presenter: jean-philippe Jacquin
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
3647 - Real-life data on the cardiac toxicity of adjuvant fixed-dose subcutaneous trastuzumab in HER2-positive breast cancer.
Presenter: Rita De Sanctis
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
3837 - Comprehensive evaluation of the pharmacokinetic profiles of SB3 and reference trastuzumab
Presenter: Xavier Pivot
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
1692 - The impact of neoadjuvant dual HER2 targeting with Pertuzumab and Trastuzumab on pathological complete response (pCR) rates: Kent Oncology Centre (KOC) experience
Presenter: Samantha Forner
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract